Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia

NCT06393452 is registered in ClinicalTrials.gov with Pelage Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06393452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06393452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia
Lead sponsor
Pelage Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2024
Completion date
October 1, 2025
Enrollment
78 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia